Lisa A. Teot - Concepedia

Author

Lisa A. Teot

Boston Children's Hospital

Also Known As

L A Teot, L Teot, L Téot, L. A. Teot, L. Teot, L. Téot, L.A. Teot, LA Teot, LISA A. TEOT, LISA TEOT

149

Publications

8.5K

Citations

H-Index

104

Concepts

All Affiliations

Boston Children's Hospital University of Southern California Harvard University Children's Oncology Group Boston Children's Museum

About

Lisa A. Teot is an author at Boston Children's Hospital specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	34	1.5K
2	Health Sciences	7	7	132
3	Public Health	3	3	291
4	Social Sciences	1	1	52
5	Anatomy	1	1	22

Lisa A. Teot

Publications

6.7K

Citations

H-Index

Page 1

	Year	Citations
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort Sigbjørn Smeland, Stefan Bielack, Jeremy Whelan, European Journal of Cancer	2019	700
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial Neyssa Marina, Sigbjørn Smeland, Stefan Bielack, The Lancet Oncology	2016	511
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan, Journal of Clinical Oncology	2015	412
Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803 Carola A.S. Arndt, Julie A. Stoner, Douglas S. Hawkins, Journal of Clinical Oncology	2009	363
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment Jeremy Whelan, Stefan Bielack, Neyssa Marina, Annals of Oncology	2014	321
EWSR1‐CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma Cristina R. Antonescu, Paola Dal Cin, Khédoudja Nafa, Genes Chromosomes and Cancer	2007	294
An Immunohistochemical Algorithm to Facilitate Diagnosis and Subtyping of Rhabdomyosarcoma: The Childrenʼs Oncology Group Experience Raffaella Morotti, Kathleen Nicol, David M. Parham, The American Journal of Surgical Pathology Embryonal RmsSurgical OncologyTumoral PathologyMalignant DiseaseRms Cases	2006	202
The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group Erin R. Rudzinski, James R. Anderson, Douglas S. Hawkins, Archives of Pathology & Laboratory Medicine	2015	180
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group Douglas S. Hawkins, Yueh-Yun Chi, James R. Anderson, Journal of Clinical Oncology	2018	170
Amniotic fluid interleukin-6 levels correlate with histologic chorioamnionitis and amniotic fluid cultures in patients in premature labor with intact membranes Phillip C. Greig, J.M. Ernest, Lisa A. Teot, American Journal of Obstetrics and Gynecology Maternal ImmunizationAmniotic Fluid CulturesIntact MembranesPreterm LaborPremature Labor	1993	145

Page 1